Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436545 | 0.96 | KDM4E (0.52) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL19436543 | 0.96 | KDM4E (0.52) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL29626051 | 0.96 | KDM4E (0.52) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28414327 | 0.93 | STING1 (0.52) | KDM4EALDH1A1SMN1; SMN2STING1CYP2D6 | |
| SCHEMBL19451497 | 0.93 | STING1 (0.52) | KDM4EALDH1A1SMN1; SMN2STING1CYP2D6 | |
| SCHEMBL19436485 | 0.92 | KDM4E (0.56) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL19451647 | 0.92 | KDM4E (0.56) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22571859 | 0.90 | STING1 (0.50) | KDM4ESMN1; SMN2STING1CYP2D6LMNA | |
| SCHEMBL31016375 | 0.89 | STING1 (0.49) | KDM4ESMN1; SMN2STING1CYP2D6LMNA | |
| SCHEMBL24465478 | 0.88 | KDM4E (0.53) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | STING1, CGAS, TLR9 | KDM4E 3457/4885NPC1 655/4885ALDH1A1 4653/4885 |
| US-20180105514-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | RB1, RBBP5, RCC2 | KDM4E 2480/4885NPC1 4662/4885ALDH1A1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.